The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders

Joseph Patrick McEvoy, Tyson Park, Traci Schilling, Emi Terasawa, Rajeev Ayyagari, Benjamin Carroll

Research output: Contribution to journalArticle

Abstract

Objective: To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications. Methods: Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder or bipolar disorder were extracted from a Medicaid claims database. Separate cohorts of TD patients with and without other EPS (“TD + EPS” and “TD non-EPS”) were constructed and matched to patients in a non-TD/EPS control cohort at a ∼1:5 ratio. HRU outcomes were assessed using descriptive statistics and difference-in-differences techniques over baseline and follow-up periods defined as the 6 months before and after TD development, respectively. Results: The TD + EPS (n = 289) and TD non-EPS (n = 394) cohorts were matched with 1398 and 1922 control patients, respectively. The percentage of patients with all-cause and mental-disorder-related inpatient admissions increased from baseline to follow-up in the TD + EPS (12.8% and 12.5%, respectively) and TD non-EPS (16.0% and 13.5%) cohorts; by contrast, slight decreases (∼3%) in these outcomes were observed in the matched controls. Difference-in-differences analyses demonstrated that development of TD was associated with a statistically significant increase of ∼15–19% in the percentage of patients with all-cause and mental-disorder-related inpatient admissions/visits. The within-cohort change from baseline to follow-up in the use of potential drugs for TD or EPS was similar between the TD cohorts and their matched controls. Conclusions: This study demonstrates a significant economic burden associated with developing TD, as captured by increased HRU including inpatient admissions and ER visits.

Original languageEnglish (US)
Pages (from-to)1205-1214
Number of pages10
JournalCurrent Medical Research and Opinion
Volume35
Issue number7
DOIs
StatePublished - Jul 3 2019

Fingerprint

Mental Disorders
Antipsychotic Agents
Inpatients
Delivery of Health Care
Tardive Dyskinesia
Dyskinesias
Medicaid
Major Depressive Disorder
Bipolar Disorder
Schizophrenia
Economics
Databases

Keywords

  • Antipsychotics
  • extrapyramidal symptoms
  • healthcare resource utilization
  • tardive dyskinesia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. / McEvoy, Joseph Patrick; Park, Tyson; Schilling, Traci; Terasawa, Emi; Ayyagari, Rajeev; Carroll, Benjamin.

In: Current Medical Research and Opinion, Vol. 35, No. 7, 03.07.2019, p. 1205-1214.

Research output: Contribution to journalArticle

McEvoy, Joseph Patrick ; Park, Tyson ; Schilling, Traci ; Terasawa, Emi ; Ayyagari, Rajeev ; Carroll, Benjamin. / The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. In: Current Medical Research and Opinion. 2019 ; Vol. 35, No. 7. pp. 1205-1214.
@article{d66f78850c09496c969f744940f6dba9,
title = "The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders",
abstract = "Objective: To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications. Methods: Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder or bipolar disorder were extracted from a Medicaid claims database. Separate cohorts of TD patients with and without other EPS (“TD + EPS” and “TD non-EPS”) were constructed and matched to patients in a non-TD/EPS control cohort at a ∼1:5 ratio. HRU outcomes were assessed using descriptive statistics and difference-in-differences techniques over baseline and follow-up periods defined as the 6 months before and after TD development, respectively. Results: The TD + EPS (n = 289) and TD non-EPS (n = 394) cohorts were matched with 1398 and 1922 control patients, respectively. The percentage of patients with all-cause and mental-disorder-related inpatient admissions increased from baseline to follow-up in the TD + EPS (12.8{\%} and 12.5{\%}, respectively) and TD non-EPS (16.0{\%} and 13.5{\%}) cohorts; by contrast, slight decreases (∼3{\%}) in these outcomes were observed in the matched controls. Difference-in-differences analyses demonstrated that development of TD was associated with a statistically significant increase of ∼15–19{\%} in the percentage of patients with all-cause and mental-disorder-related inpatient admissions/visits. The within-cohort change from baseline to follow-up in the use of potential drugs for TD or EPS was similar between the TD cohorts and their matched controls. Conclusions: This study demonstrates a significant economic burden associated with developing TD, as captured by increased HRU including inpatient admissions and ER visits.",
keywords = "Antipsychotics, extrapyramidal symptoms, healthcare resource utilization, tardive dyskinesia",
author = "McEvoy, {Joseph Patrick} and Tyson Park and Traci Schilling and Emi Terasawa and Rajeev Ayyagari and Benjamin Carroll",
year = "2019",
month = "7",
day = "3",
doi = "10.1080/03007995.2019.1569871",
language = "English (US)",
volume = "35",
pages = "1205--1214",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders

AU - McEvoy, Joseph Patrick

AU - Park, Tyson

AU - Schilling, Traci

AU - Terasawa, Emi

AU - Ayyagari, Rajeev

AU - Carroll, Benjamin

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Objective: To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications. Methods: Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder or bipolar disorder were extracted from a Medicaid claims database. Separate cohorts of TD patients with and without other EPS (“TD + EPS” and “TD non-EPS”) were constructed and matched to patients in a non-TD/EPS control cohort at a ∼1:5 ratio. HRU outcomes were assessed using descriptive statistics and difference-in-differences techniques over baseline and follow-up periods defined as the 6 months before and after TD development, respectively. Results: The TD + EPS (n = 289) and TD non-EPS (n = 394) cohorts were matched with 1398 and 1922 control patients, respectively. The percentage of patients with all-cause and mental-disorder-related inpatient admissions increased from baseline to follow-up in the TD + EPS (12.8% and 12.5%, respectively) and TD non-EPS (16.0% and 13.5%) cohorts; by contrast, slight decreases (∼3%) in these outcomes were observed in the matched controls. Difference-in-differences analyses demonstrated that development of TD was associated with a statistically significant increase of ∼15–19% in the percentage of patients with all-cause and mental-disorder-related inpatient admissions/visits. The within-cohort change from baseline to follow-up in the use of potential drugs for TD or EPS was similar between the TD cohorts and their matched controls. Conclusions: This study demonstrates a significant economic burden associated with developing TD, as captured by increased HRU including inpatient admissions and ER visits.

AB - Objective: To assess the impact of developing tardive dyskinesia (TD), both with and without other pre-existing extrapyramidal symptoms (EPS), on healthcare resource utilization (HRU) among patients with mental disorders receiving antipsychotic medications. Methods: Data on patients receiving antipsychotics who had schizophrenia, major depressive disorder or bipolar disorder were extracted from a Medicaid claims database. Separate cohorts of TD patients with and without other EPS (“TD + EPS” and “TD non-EPS”) were constructed and matched to patients in a non-TD/EPS control cohort at a ∼1:5 ratio. HRU outcomes were assessed using descriptive statistics and difference-in-differences techniques over baseline and follow-up periods defined as the 6 months before and after TD development, respectively. Results: The TD + EPS (n = 289) and TD non-EPS (n = 394) cohorts were matched with 1398 and 1922 control patients, respectively. The percentage of patients with all-cause and mental-disorder-related inpatient admissions increased from baseline to follow-up in the TD + EPS (12.8% and 12.5%, respectively) and TD non-EPS (16.0% and 13.5%) cohorts; by contrast, slight decreases (∼3%) in these outcomes were observed in the matched controls. Difference-in-differences analyses demonstrated that development of TD was associated with a statistically significant increase of ∼15–19% in the percentage of patients with all-cause and mental-disorder-related inpatient admissions/visits. The within-cohort change from baseline to follow-up in the use of potential drugs for TD or EPS was similar between the TD cohorts and their matched controls. Conclusions: This study demonstrates a significant economic burden associated with developing TD, as captured by increased HRU including inpatient admissions and ER visits.

KW - Antipsychotics

KW - extrapyramidal symptoms

KW - healthcare resource utilization

KW - tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=85061779488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061779488&partnerID=8YFLogxK

U2 - 10.1080/03007995.2019.1569871

DO - 10.1080/03007995.2019.1569871

M3 - Article

C2 - 30638073

AN - SCOPUS:85061779488

VL - 35

SP - 1205

EP - 1214

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 7

ER -